Floatz logo

[68ga]ga-nota-r8b4

Nasopharyngeal Carcinoma

Explore 44 assets in Nasopharyngeal Carcinoma →
Floatz Rating
CCC53/100
Confidence
Indicative
v0.2
Sponsor
RenJi Hospital
Modality
radiopharmaceutical
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2

Clinical Evidence

Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
38Indicative
Detailed axis rationale is planned and will be published soon.
TrialPhaseStatusNPrimary endpointReadout
NCT06852638CT.gov
CD70-targeted immunoPET Imaging of Malignant Cancers
—Recruiting———

Competitive Position

Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
81High confidence
Detailed axis rationale is planned and will be published soon.

Same indication · Nasopharyngeal Carcinoma

AssetSponsorPhaseRating
[68ga]ga-nota-r8b4 (this asset)RenJi HospitalP2CCC · 53
IrinotecanM.D. Anderson Cancer CenterP2B
OxaliplatinNational Cancer Institute (NCI)P2B
Immunoglobulin G1 [De-448-Lysine], Anti-(Human Epidermal Growth Factor Receptor) (Human-Mouse Monoclonal C225 ?1-Chain) Fusion Protein With Peptide Linker (Ggggs)2 Fusion Protein With Immunoglobulin Anti-(Human Epidermal Growth Factor Receptor Her3) (Human Clone Her3.H3 Single-Chain Variable Fragment Vh-(Ggggs)3-Vl), Complex With Human-Mouse Monoclonal C225 ?-Chain, Dimer, 214??,214???,222,222?,228,228?,231,231?-Octakis(Thioether) With (2S)-N-(Carboxymethyl)-2-(3-Mercapto-2,5-Dioxo-1-Pyrrolidinyl)-?-Alanylglycylglycyl-L-Phenylalanyl-N-[[(1S)-2-[[(1S,9S)-9-Ethyl-5-Fluoro-2,3,9,10,13,15-Hexahydro-9-Hydroxy-4-Methyl-10,13-Dioxo-1H,12H-Benzo[De]Pyrano[3?,4?:6,7]Indolizino[1,2-B]Quinolin-1-Yl]Amino]-1-Methyl-2-Oxoethoxy]Methyl]GlycinamideSichuan Baili Pharmaceutical Co., Ltd.P2B
IpilimumabXencor, Inc.P2B
[68ga]ga-nota-t4RenJi HospitalP2/3B
[18f]f-resca-rt4RenJi HospitalP2/3B
[18F]F-RESCA-T4RenJi HospitalP2/3B
[68ga]ga-nota-rt4RenJi HospitalP2/3B

+42 more in the Nasopharyngeal Carcinoma cohort

Other indications for [68ga]ga-nota-r8b4

IndicationSponsorPhaseRating
Renal Cell Carcinoma—P2CCC · 53
Clear Cell Renal Carcinoma—P2CCC · 53
Diffuse Large B-Cell Lymphoma—P2CCC · 53

Scientific Foundation

Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR

Planned for methodology v0.2.

Development Feasibility

How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR

Planned for methodology v0.2.

Commercial Opportunity

Commercial prize: addressable population, unmet need, and the value case for the indication.
NR

Planned for methodology v0.2.

IP & Exclusivity

Exclusivity position, covering patent protection and freedom-to-operate runway.
NR

Planned for methodology v0.2.

Manufacturing & Supply

Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR

Planned for methodology v0.2.

Related assets

Citation

Floatz Terminal. [68ga]ga-nota-r8b4 in Nasopharyngeal Carcinoma. Methodology v0.2.
Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026.
Accessed July 14, 2026.
https://terminal.floatz.ai/assets/68gaga-nota-r8b4-nasopharyngeal-carcinoma

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →